<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26080652</article-id><article-id pub-id-type="pmc">4745028</article-id><article-id pub-id-type="doi">10.1111/dom.12494</article-id><article-id pub-id-type="publisher-id">DOM12494</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4&#x02010;week, randomized, placebo&#x02010;controlled trial (<styled-content style="fixed-case">EASE</styled-content>&#x02010;1)</article-title><alt-title alt-title-type="left-running-head">Pieber et al</alt-title></title-group><contrib-group><contrib id="dom12494-cr-0001" contrib-type="author" corresp="yes"><name><surname>Pieber</surname><given-names>T. R.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0001">
<sup>1</sup>
</xref><xref ref-type="author-note" rid="dom12494-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="dom12494-cr-0002" contrib-type="author"><name><surname>Famulla</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0002">
<sup>2</sup>
</xref><xref ref-type="author-note" rid="dom12494-note-0001">
<sup>&#x02020;</sup>
</xref></contrib><contrib id="dom12494-cr-0003" contrib-type="author"><name><surname>Eilbracht</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="dom12494-cr-0004" contrib-type="author"><name><surname>Cescutti</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="dom12494-cr-0005" contrib-type="author"><name><surname>Soleymanlou</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="dom12494-cr-0006" contrib-type="author"><name><surname>Johansen</surname><given-names>O. E.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="dom12494-cr-0007" contrib-type="author"><name><surname>Woerle</surname><given-names>H. J.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="dom12494-cr-0008" contrib-type="author"><name><surname>Broedl</surname><given-names>U. C.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="dom12494-cr-0009" contrib-type="author"><name><surname>Kaspers</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="dom12494-aff-0007">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="dom12494-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Division of Endocrinology and Metabolism, Department of Internal Medicine</named-content><institution>Medical University of Graz</institution><named-content content-type="city">Graz</named-content><country country="AT">Austria</country></aff><aff id="dom12494-aff-0002"><label><sup>2</sup></label><institution>Profil</institution><named-content content-type="city">Neuss</named-content><country country="DE">Germany</country></aff><aff id="dom12494-aff-0003"><label><sup>3</sup></label><institution>Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG</institution><named-content content-type="city">Biberach</named-content><country country="DE">Germany</country></aff><aff id="dom12494-aff-0004"><label><sup>4</sup></label><institution>Boehringer Ingelheim France</institution><named-content content-type="city">Reims</named-content><country country="FR">France</country></aff><aff id="dom12494-aff-0005"><label><sup>5</sup></label><institution>Boehringer Ingelheim Canada Ltd./Ltee</institution><named-content content-type="city">Burlington</named-content><country country="CA">Canada</country></aff><aff id="dom12494-aff-0006"><label><sup>6</sup></label><institution>Boehringer Ingelheim Norway K.S</institution><named-content content-type="city">Asker</named-content><country country="NO">Norway</country></aff><aff id="dom12494-aff-0007"><label><sup>7</sup></label><institution>Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG</institution><named-content content-type="city">Ingelheim</named-content><country country="DE">Germany</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><italic>Correspondence to</italic>: Thomas R. Pieber, Medical University Graz, Auenbruggerplatz 15, A&#x02010;8036 Graz, Austria.<break/>
E&#x02010;mail: <email>thomas.pieber@medunigraz.at</email><break/></corresp><fn id="dom12494-note-0001"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2015</year></pub-date><volume>17</volume><issue>10</issue><issue-id pub-id-type="doi">10.1111/dom.2015.17.issue-10</issue-id><fpage>928</fpage><lpage>935</lpage><history><date date-type="received"><day>10</day><month>2</month><year>2015</year></date><date date-type="rev-recd"><day>06</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2015 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Diabetes, Obesity and Metabolism published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-17-928.pdf"/><abstract id="dom12494-abs-0001"><sec id="dom12494-sec-0001"><title>Aims</title><p id="dom12494-para-0001">To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes.</p></sec><sec id="dom12494-sec-0002"><title>Methods</title><p id="dom12494-para-0002">A total of 75 patients with glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) concentrations of &#x02265;7.5 to &#x02264;10.5% (&#x02265;58 to &#x02264;91&#x02009;mmol/mol) were randomized to receive once&#x02010;daily empagliflozin 2.5&#x02009;mg, empagliflozin 10&#x02009;mg, empagliflozin 25&#x02009;mg, or placebo as adjunct to insulin for 28&#x02009;days. Insulin dose was to be kept as stable as possible for 7&#x02009;days then adjusted, at the investigator's discretion, to achieve optimum glycaemic control. The primary exploratory endpoint was change from baseline in 24&#x02010;h urinary glucose excretion (<styled-content style="fixed-case">UGE</styled-content>) on day&#x02009;7.</p></sec><sec id="dom12494-sec-0003"><title>Results</title><p id="dom12494-para-0003">Empagliflozin significantly increased 24&#x02010;h <styled-content style="fixed-case">UGE</styled-content> versus placebo on days&#x02009;7 and 28. On day&#x02009;28, adjusted mean differences with empagliflozin versus placebo in changes from baseline in: <styled-content style="fixed-case">HbA1c</styled-content> were &#x02212;0.35 to &#x02212;0.49% (&#x02212;3.8 to &#x02212;5.4&#x02009;mmol/mol; all p&#x02009;&#x0003c;&#x02009;0.05 vs. placebo); total daily insulin dose &#x02212;0.07 to &#x02212;0.09&#x02009;<styled-content style="fixed-case">U/kg</styled-content> (all p&#x0003c;0.05 vs placebo); and weight were &#x02212;1.5 to &#x02212;1.9&#x02009;kg (all p&#x02009;&#x0003c;&#x02009;0.001 vs. placebo). In the placebo, empagliflozin 2.5, 10 and 25&#x02009;mg groups, respectively, adverse events were reported in 94.7, 89.5, 78.9 and 100.0% of patients, and the rate of symptomatic hypoglycaemic episodes with glucose &#x02264;3.0&#x02009;mmol/l not requiring assistance was 1.0, 0.4, 0.5 and 0.8 episodes per 30&#x02009;days.</p></sec><sec id="dom12494-sec-0004"><title>Conclusions</title><p id="dom12494-para-0004">In patients with type 1 diabetes, empagliflozin for 28&#x02009;days as adjunct to insulin increased <styled-content style="fixed-case">UGE</styled-content>, improved <styled-content style="fixed-case">HbA1c</styled-content> and reduced weight with lower insulin doses compared with placebo and without increasing hypoglycaemia.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12494-kwd-0001">pharmacodynamics</kwd><kwd id="dom12494-kwd-0002">pharmacology</kwd><kwd id="dom12494-kwd-0003"><styled-content style="fixed-case">SGLT2</styled-content> inhibitor</kwd><kwd id="dom12494-kwd-0004">type 1 diabetes</kwd></kwd-group><funding-group><award-group><funding-source>Boehringer Ingelheim</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly</funding-source></award-group></funding-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12494</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.6 mode:remove_FC converted:04.02.2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="dom12494-sec-0005"><title>Introduction</title><p id="dom12494-para-0005">Insulin therapy is an essential part of the management of type 1 diabetes <xref rid="dom12494-bib-0001" ref-type="ref">1</xref>, but is often associated with weight gain and hypoglycaemia <xref rid="dom12494-bib-0002" ref-type="ref">2</xref>, <xref rid="dom12494-bib-0003" ref-type="ref">3</xref>. Despite advances in insulin formulation and delivery, patients with type 1 diabetes often fail to reach the target HbA1c of &#x0003c;7% <xref rid="dom12494-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12494-bib-0004" ref-type="ref">4</xref>. Inadequate glucose control can lead to acute conditions such as ketoacidosis <xref rid="dom12494-bib-0005" ref-type="ref">5</xref>, and to chronic complications including retinopathy, nephropathy and cardiovascular disease <xref rid="dom12494-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12494-bib-0007" ref-type="ref">7</xref>, <xref rid="dom12494-bib-0008" ref-type="ref">8</xref>. Compared with the general population, the risk of cardiovascular disease is nearly eight times greater in patients with type 1 diabetes <xref rid="dom12494-bib-0007" ref-type="ref">7</xref>, and the increased risk of mortality from heart disease is even greater <xref rid="dom12494-bib-0009" ref-type="ref">9</xref>.</p><p id="dom12494-para-0006">Empagliflozin is a potent and selective inhibitor of the sodium glucose cotransporter 2 (SGLT2) <xref rid="dom12494-bib-0010" ref-type="ref">10</xref> that inhibits renal glucose reabsorption and thus increases urinary glucose excretion (UGE) in patients with diabetes <xref rid="dom12494-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12494-bib-0012" ref-type="ref">12</xref>. In patients with type 2 diabetes, empagliflozin given as monotherapy or as add&#x02010;on therapy (including as add&#x02010;on to basal insulin or multiple daily injections of insulin) has consistently been shown to improve glycaemic control and reduce blood pressure and weight, with a low risk of hypoglycaemia <xref rid="dom12494-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12494-bib-0014" ref-type="ref">14</xref>, <xref rid="dom12494-bib-0015" ref-type="ref">15</xref>, <xref rid="dom12494-bib-0016" ref-type="ref">16</xref>, <xref rid="dom12494-bib-0017" ref-type="ref">17</xref>, <xref rid="dom12494-bib-0018" ref-type="ref">18</xref>.</p><p id="dom12494-para-0007">As the mechanism of action of SGLT2 inhibitors is independent of the action of insulin <xref rid="dom12494-bib-0019" ref-type="ref">19</xref>, these agents have the potential to be used as an adjunct to insulin to improve glycaemic control in patients with type 1 diabetes. In an 8&#x02010;week single&#x02010;arm pilot study in patients with type 1 diabetes, empagliflozin as adjunct to insulin led to significant reductions in glycated haemoglobin (HbA1c), fasting glucose, blood pressure, weight and the frequency of symptomatic hypoglycaemic events with plasma glucose &#x0003c;3.0&#x02009;mmol/l <xref rid="dom12494-bib-0012" ref-type="ref">12</xref>.</p><p id="dom12494-para-0008">The objectives of this trial (EASE&#x02010;1) were to investigate the pharmacodynamics, efficacy and safety of empagliflozin 2.5, 10 and 25&#x02009;mg administered as adjunct to a basal&#x02010;bolus insulin regimen in patients with type 1 diabetes.</p></sec><sec id="dom12494-sec-0006"><title>Materials and Methods</title><sec id="dom12494-sec-0007"><title>Study Design</title><p id="dom12494-para-0009">This was a randomized, double&#x02010;blind, placebo&#x02010;controlled, parallel&#x02010;group, phase II study conducted in one centre in Germany and one centre in Austria between 25 November 2013 and 20 April 2014 (File S1). The clinical trial protocol was approved by the Institutional Review Boards and Independent Ethics Committees and Competent Authorities of the participating centres, and the study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical Practice. The trial was registered with <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01969747). All patients provided written informed consent.</p></sec><sec id="dom12494-sec-0008"><title>Inclusion and Exclusion Criteria</title><p id="dom12494-para-0010">This study enrolled patients with type 1 diabetes aged &#x02265;18 to &#x02264;65&#x02009;years with a body mass index (BMI) 18.5&#x02013;35&#x02009;kg/m<sup>2</sup>, HbA1c &#x02265;7.5 to &#x02264;10.5% (&#x02265;58 to &#x02264;91&#x02009;mmol/mol), estimated glomerular filtration rate (eGFR; Chronic Kidney Disease Epidemiology Collaboration formula) &#x02265;60 to &#x02264;150&#x02009;ml/min/1.73m<sup>2</sup> and C&#x02010;peptide &#x0003c;1.5&#x02009;ng/ml. To be included in the study, patients had to have received multiple daily injections of insulin, consisting of basal insulin and &#x02265;3 daily bolus injections, for &#x02265;12&#x02009;months before screening. Total daily insulin requirement had to be &#x02264;1.5&#x02009;U/kg at screening and the insulin administration algorithm had to have been stable for &#x02265;12&#x02009;weeks before screening.</p><p id="dom12494-para-0011">Exclusion criteria included acute symptomatic urinary tract infection (UTI) or genital infection; chronic or recurrent (&#x02265;3 annual episodes) cystitis; treatment with any antihyperglycaemic drug except insulin in the 3&#x02009;months before screening; hypoglycaemia that required hospitalization or emergency treatment in the 3&#x02009;months before screening; unawareness of hypoglycaemia (investigator's judgment); &#x02265;2 unexplained hypoglycaemic episodes in the 3&#x02009;months before screening; diabetic ketoacidosis that required hospitalization or emergency treatment in the 12&#x02009;months before screening; brittle diabetes (investigator's judgement); alanine transaminase, aspartate transaminase or alkaline phosphatase &#x0003e;3&#x02009;&#x000d7;&#x02009;upper limit of normal at screening; treatment with anti&#x02010;obesity drugs, surgery or aggressive diet leading to unstable body weight 3&#x02009;months before screening; any other investigational drug intake within 30&#x02009;days of study drug intake.</p></sec><sec id="dom12494-sec-0009"><title>Treatment and Interventions</title><p id="dom12494-para-0012">After a 2&#x02010;week, open&#x02010;label, placebo run&#x02010;in period, eligible patients were randomized in a 1&#x02009;:&#x02009;1&#x02009;:&#x02009;1&#x02009;:&#x02009;1 ratio to receive once&#x02010;daily empagliflozin 2.5&#x02009;mg, empagliflozin 10&#x02009;mg, empagliflozin 25&#x02009;mg, or placebo as adjunct to insulin for 28&#x02009;days. Randomization was undertaken using a third&#x02010;party interactive voice and web response system, and was stratified by site. The insulin regimen was to be kept stable (no change to basal insulin dose, insulin&#x02010;to&#x02010;carbohydrate ratio, or correction factor for bolus insulin) during the first 7&#x02009;days of treatment (stable insulin period), then was freely adjustable according to the investigator's judgement to achieve optimum glycaemic control for the remaining 21&#x02009;days of treatment (flexible insulin period). In cases of hypoglycaemia during the stable insulin period, patients were to ingest carbohydrates; however, insulin could be adjusted for safety reasons at any time if deemed necessary by the investigator.</p><p id="dom12494-para-0013">Patients were admitted to the study site from 2&#x02009;days before drug administration to day&#x02009;8 of drug administration. Patients were called by site personnel on day&#x02009;9 to discuss insulin adjustments, and further telephone calls were agreed upon as needed. Patients returned for ambulatory visits on days 14, 21 and 27, and stayed at the study site overnight on day&#x02009;28. Patients returned for a follow&#x02010;up visit 7&#x02009;days after the end of treatment. For determination of 24&#x02010;h UGE, all urine voided during 24&#x02009;h was collected at baseline and on days&#x02009;1, 7 and 28.</p><p id="dom12494-para-0014">Patients received diet and exercise counselling based on local recommendations at the start of the run&#x02010;in period and were reminded to follow their usual diet and exercise plan at every study visit. Patients were instructed to keep their diet and daily carbohydrate intake as stable as possible throughout the trial. Patients were provided with a self&#x02010;monitoring of blood glucose device. Self&#x02010;monitoring of blood glucose was performed before breakfast, lunch and dinner and at bedtime, with additional tests as recommended by the investigator, or if a patient experienced signs or symptoms of hyper&#x02010; or hypoglycaemia. Patients were asked to record in an electronic diary their insulin dose, carbohydrate intake, blood glucose and blood ketones throughout the treatment and follow&#x02010;up periods.</p></sec><sec id="dom12494-sec-0010"><title>Endpoints and Assessments</title><p id="dom12494-para-0015">The primary endpoint was exploratory and was the change from baseline in 24&#x02010;h UGE on day&#x02009;7. Other endpoints included: change from baseline in 24&#x02010;h UGE on day&#x02009;28; change from baseline in HbA1c on day&#x02009;28; change from baseline in fasting plasma glucose (FPG) on days&#x02009;7 and 28; change from baseline in mean daily glucose (MDG; eight&#x02010;point profile) on days&#x02009;7 and 28; change from baseline in weekly mean recorded total insulin use in the fourth week of treatment; change from baseline in weight on day&#x02009;28; and changes from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) on day&#x02009;28.</p><p id="dom12494-para-0016">Safety endpoints included vital signs, clinical laboratory variables and adverse events (AEs) with onset between the first intake of study drug and up to 7&#x02009;days after the last dose of study drug [coded using preferred terms in the Medical Dictionary for Drug Regulatory Activities (MedDRA) version 17.0]. Rates of hypoglycaemic episodes per 30&#x02009;days were based on episodes with onset between the first intake of study drug and up to 1&#x02009;day after the last dose of study drug. Events consistent with UTI and genital infections were identified using prospectively defined search categories based on 73 and 89 MedDRA preferred terms, respectively.</p></sec><sec id="dom12494-sec-0011"><title>Statistical Analysis</title><p id="dom12494-para-0017">Sample size calculations indicated that 72 patients (18 per treatment group) would provide &#x02265;95% power to detect a difference in the primary endpoint of 65&#x02009;g/24&#x02009;h for empagliflozin 10&#x02009;mg compared with placebo and 79&#x02009;g/24&#x02009;h for empagliflozin 25&#x02009;mg compared with placebo, assuming a standard deviation of 5, 29 and 27 for placebo, empagliflozin 10&#x02009;mg and empagliflozin 25&#x02009;mg respectively, with a two&#x02010;sided significance level of 0.05.</p><p id="dom12494-para-0018">Pharmacodynamic and efficacy analyses were performed on the full analysis set, which included patients treated with &#x02265;1 dose of study drug who had a 24&#x02010;h UGE measurement at baseline and at day&#x02009;1 and/or day&#x02009;7. Safety analyses were descriptive and were performed on the treated set (patients treated with &#x02265;1 dose of study drug).</p><p id="dom12494-para-0019">The primary endpoint was assessed using an analysis of covariance (<sc>ancova</sc>) model, with treatment as a fixed effect and baseline 24&#x02010;h UGE as a continuous covariate. A last observation carried forward (LOCF) approach was used to impute missing data. Changes from baseline in other efficacy endpoints were analysed using an <sc>ancova</sc> model, with treatment as a fixed effect and the baseline value for the respective endpoint as a linear covariate. The <sc>ancova</sc> model for MDG on days&#x02009;7 and 28 included weekly mean recorded insulin dose at week&#x02009;1 and week&#x02009;4, respectively, as an additional linear covariate. UGE, insulin dose and carbohydrate intake over time were analysed descriptively.</p></sec></sec><sec id="dom12494-sec-0012"><title>Results</title><sec id="dom12494-sec-0013"><title>Patients</title><p id="dom12494-para-0020">A total of 75 patients were randomized and treated with placebo (n&#x02009;=&#x02009;19), empagliflozin 2.5&#x02009;mg (n&#x02009;=&#x02009;19), empagliflozin 10&#x02009;mg (n&#x02009;=&#x02009;19), or empagliflozin 25&#x02009;mg (n&#x02009;=&#x02009;18). No patients prematurely discontinued from the study. Baseline characteristics were similar across treatment groups, except for a higher mean BMI in the empagliflozin 10&#x02009;mg group and a higher proportion of females in the empagliflozin 25&#x02009;mg group (Table <xref rid="dom12494-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="dom12494-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient demographics and baseline characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12494-ent-0001" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="dom12494-ent-0002" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Placebo</bold>
</th><th id="dom12494-ent-0003" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Empagliflozin 2.5&#x02009;mg</bold>
</th><th id="dom12494-ent-0004" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Empagliflozin 10&#x02009;mg</bold>
</th><th id="dom12494-ent-0005" align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Empagliflozin 25&#x02009;mg</bold>
</th></tr></thead><tbody valign="top"><tr><td id="dom12494-ent-0006" align="left" valign="top" rowspan="1" colspan="1">Number of patients</td><td id="dom12494-ent-0007" align="left" valign="top" rowspan="1" colspan="1">19</td><td id="dom12494-ent-0008" align="left" valign="top" rowspan="1" colspan="1">19</td><td id="dom12494-ent-0009" align="left" valign="top" rowspan="1" colspan="1">19</td><td id="dom12494-ent-0010" align="left" valign="top" rowspan="1" colspan="1">18</td></tr><tr><td id="dom12494-ent-0011" align="left" valign="top" rowspan="1" colspan="1">Male</td><td id="dom12494-ent-0012" align="left" valign="top" rowspan="1" colspan="1">13 (68.4)</td><td id="dom12494-ent-0013" align="left" valign="top" rowspan="1" colspan="1">15 (78.9)</td><td id="dom12494-ent-0014" align="left" valign="top" rowspan="1" colspan="1">15 (78.9)</td><td id="dom12494-ent-0015" align="left" valign="top" rowspan="1" colspan="1">10 (55.6)</td></tr><tr><td id="dom12494-ent-0016" align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td id="dom12494-ent-0017" align="left" valign="top" rowspan="1" colspan="1">40.5 (10.6)</td><td id="dom12494-ent-0018" align="left" valign="top" rowspan="1" colspan="1">41.9 (12.4)</td><td id="dom12494-ent-0019" align="left" valign="top" rowspan="1" colspan="1">39.6 (11.6)</td><td id="dom12494-ent-0020" align="left" valign="top" rowspan="1" colspan="1">41.9 (9.7)</td></tr><tr><td colspan="5" align="left" id="dom12494-ent-0021" valign="top" rowspan="1">Race</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0022" align="left" valign="top" rowspan="1" colspan="1">White</td><td id="dom12494-ent-0023" align="left" valign="top" rowspan="1" colspan="1">19 (100.0)</td><td id="dom12494-ent-0024" align="left" valign="top" rowspan="1" colspan="1">19 (100.0)</td><td id="dom12494-ent-0025" align="left" valign="top" rowspan="1" colspan="1">19 (100.0)</td><td id="dom12494-ent-0026" align="left" valign="top" rowspan="1" colspan="1">18 (100.0)</td></tr><tr><td id="dom12494-ent-0027" align="left" valign="top" rowspan="1" colspan="1">Time since diagnosis of type 1 diabetes, years</td><td id="dom12494-ent-0028" align="left" valign="top" rowspan="1" colspan="1">20.5 (12.8)</td><td id="dom12494-ent-0029" align="left" valign="top" rowspan="1" colspan="1">19.9 (12.0)</td><td id="dom12494-ent-0030" align="left" valign="top" rowspan="1" colspan="1">16.2 (8.4)</td><td id="dom12494-ent-0031" align="left" valign="top" rowspan="1" colspan="1">23.7 (14.5)</td></tr><tr><td colspan="5" align="left" id="dom12494-ent-0032" valign="top" rowspan="1">Time since diagnosis of type 1 diabetes</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0033" align="left" valign="top" rowspan="1" colspan="1">&#x02264;5&#x02009;years</td><td id="dom12494-ent-0034" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0035" align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td><td id="dom12494-ent-0036" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0037" align="left" valign="top" rowspan="1" colspan="1">2 (11.1)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0038" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;5&#x02013;10&#x02009;years</td><td id="dom12494-ent-0039" align="left" valign="top" rowspan="1" colspan="1">4 (21.1)</td><td id="dom12494-ent-0040" align="left" valign="top" rowspan="1" colspan="1">3 (15.8)</td><td id="dom12494-ent-0041" align="left" valign="top" rowspan="1" colspan="1">6 (31.6)</td><td id="dom12494-ent-0042" align="left" valign="top" rowspan="1" colspan="1">2 (11.1)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0043" align="left" valign="top" rowspan="1" colspan="1">&#x0003e;10&#x02009;years</td><td id="dom12494-ent-0044" align="left" valign="top" rowspan="1" colspan="1">15 (78.9)</td><td id="dom12494-ent-0045" align="left" valign="top" rowspan="1" colspan="1">15 (78.9)</td><td id="dom12494-ent-0046" align="left" valign="top" rowspan="1" colspan="1">13 (68.4)</td><td id="dom12494-ent-0047" align="left" valign="top" rowspan="1" colspan="1">14 (77.8)</td></tr><tr><td id="dom12494-ent-0048" align="left" valign="top" rowspan="1" colspan="1">Body weight, kg</td><td id="dom12494-ent-0049" align="left" valign="top" rowspan="1" colspan="1">79.8 (13.8)</td><td id="dom12494-ent-0050" align="left" valign="top" rowspan="1" colspan="1">75.9 (14.2)</td><td id="dom12494-ent-0051" align="left" valign="top" rowspan="1" colspan="1">87.1 (13.3)</td><td id="dom12494-ent-0052" align="left" valign="top" rowspan="1" colspan="1">76.9 (14.5)</td></tr><tr><td id="dom12494-ent-0053" align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td><td id="dom12494-ent-0054" align="left" valign="top" rowspan="1" colspan="1">25.4 (3.7)</td><td id="dom12494-ent-0055" align="left" valign="top" rowspan="1" colspan="1">24.7 (3.6)</td><td id="dom12494-ent-0056" align="left" valign="top" rowspan="1" colspan="1">27.4 (3.5)</td><td id="dom12494-ent-0057" align="left" valign="top" rowspan="1" colspan="1">25.4 (3.5)</td></tr><tr><td id="dom12494-ent-0058" align="left" valign="top" rowspan="1" colspan="1">HbA1c, %</td><td id="dom12494-ent-0059" align="left" valign="top" rowspan="1" colspan="1">8.18 (0.67)</td><td id="dom12494-ent-0060" align="left" valign="top" rowspan="1" colspan="1">8.35 (0.75)</td><td id="dom12494-ent-0061" align="left" valign="top" rowspan="1" colspan="1">8.28 (0.79)</td><td id="dom12494-ent-0062" align="left" valign="top" rowspan="1" colspan="1">8.15 (0.54)</td></tr><tr><td id="dom12494-ent-0063" align="left" valign="top" rowspan="1" colspan="1">HbA1c, mmol/mol</td><td id="dom12494-ent-0064" align="left" valign="top" rowspan="1" colspan="1">66 (7.3)</td><td id="dom12494-ent-0065" align="left" valign="top" rowspan="1" colspan="1">68 (8.2)</td><td id="dom12494-ent-0066" align="left" valign="top" rowspan="1" colspan="1">67 (8.6)</td><td id="dom12494-ent-0067" align="left" valign="top" rowspan="1" colspan="1">66 (5.9)</td></tr><tr><td id="dom12494-ent-0068" align="left" valign="top" rowspan="1" colspan="1">FPG, mmol/l</td><td id="dom12494-ent-0069" align="left" valign="top" rowspan="1" colspan="1">9.2 (3.7)</td><td id="dom12494-ent-0070" align="left" valign="top" rowspan="1" colspan="1">10.4 (3.6)</td><td id="dom12494-ent-0071" align="left" valign="top" rowspan="1" colspan="1">9.8 (3.6)</td><td id="dom12494-ent-0072" align="left" valign="top" rowspan="1" colspan="1">9.8 (2.8)</td></tr><tr><td id="dom12494-ent-0073" align="left" valign="top" rowspan="1" colspan="1">MDG, mmol/l</td><td id="dom12494-ent-0074" align="left" valign="top" rowspan="1" colspan="1">9.8 (2.6)</td><td id="dom12494-ent-0075" align="left" valign="top" rowspan="1" colspan="1">10.3 (2.1)</td><td id="dom12494-ent-0076" align="left" valign="top" rowspan="1" colspan="1">9.3 (2.5)</td><td id="dom12494-ent-0077" align="left" valign="top" rowspan="1" colspan="1">9.6 (2.0)</td></tr><tr><td id="dom12494-ent-0078" align="left" valign="top" rowspan="1" colspan="1">eGFR<xref ref-type="fn" rid="dom12494-note-0003">*</xref>, ml/min/1.73&#x02009;m<sup>2</sup>
</td><td id="dom12494-ent-0079" align="left" valign="top" rowspan="1" colspan="1">101.4 (14.5)</td><td id="dom12494-ent-0080" align="left" valign="top" rowspan="1" colspan="1">106.1 (10.8)</td><td id="dom12494-ent-0081" align="left" valign="top" rowspan="1" colspan="1">102.8 (15.7)</td><td id="dom12494-ent-0082" align="left" valign="top" rowspan="1" colspan="1">99.0 (13.9)</td></tr><tr><td id="dom12494-ent-0083" align="left" valign="top" rowspan="1" colspan="1">UGE, g/24&#x02009;h</td><td id="dom12494-ent-0084" align="left" valign="top" rowspan="1" colspan="1">20.3 (17.4)</td><td id="dom12494-ent-0085" align="left" valign="top" rowspan="1" colspan="1">21.4 (20.3)</td><td id="dom12494-ent-0086" align="left" valign="top" rowspan="1" colspan="1">14.0 (15.9)</td><td id="dom12494-ent-0087" align="left" valign="top" rowspan="1" colspan="1">13.4 (11.2)</td></tr><tr><td id="dom12494-ent-0088" align="left" valign="top" rowspan="1" colspan="1">SBP, mmHg</td><td id="dom12494-ent-0089" align="left" valign="top" rowspan="1" colspan="1">124.4 (15.4)</td><td id="dom12494-ent-0090" align="left" valign="top" rowspan="1" colspan="1">122.0 (13.1)</td><td id="dom12494-ent-0091" align="left" valign="top" rowspan="1" colspan="1">121.8 (13.0)</td><td id="dom12494-ent-0092" align="left" valign="top" rowspan="1" colspan="1">124.4 (13.4)</td></tr><tr><td id="dom12494-ent-0093" align="left" valign="top" rowspan="1" colspan="1">DBP, mmHg</td><td id="dom12494-ent-0094" align="left" valign="top" rowspan="1" colspan="1">76.3 (9.4)</td><td id="dom12494-ent-0095" align="left" valign="top" rowspan="1" colspan="1">74.5 (8.3)</td><td id="dom12494-ent-0096" align="left" valign="top" rowspan="1" colspan="1">72.6 (8.1)</td><td id="dom12494-ent-0097" align="left" valign="top" rowspan="1" colspan="1">72.2 (7.8)</td></tr><tr><td id="dom12494-ent-0098" align="left" valign="top" rowspan="1" colspan="1">Recorded daily basal insulin dose, U/kg</td><td id="dom12494-ent-0099" align="left" valign="top" rowspan="1" colspan="1">0.33 (0.12)</td><td id="dom12494-ent-0100" align="left" valign="top" rowspan="1" colspan="1">0.30 (0.07)</td><td id="dom12494-ent-0101" align="left" valign="top" rowspan="1" colspan="1">0.36 (0.11)</td><td id="dom12494-ent-0102" align="left" valign="top" rowspan="1" colspan="1">0.32 (0.13)</td></tr><tr><td id="dom12494-ent-0103" align="left" valign="top" rowspan="1" colspan="1">Recorded daily bolus insulin dose, U/kg</td><td id="dom12494-ent-0104" align="left" valign="top" rowspan="1" colspan="1">0.33 (0.16)</td><td id="dom12494-ent-0105" align="left" valign="top" rowspan="1" colspan="1">0.35 (0.16)</td><td id="dom12494-ent-0106" align="left" valign="top" rowspan="1" colspan="1">0.35 (0.14)</td><td id="dom12494-ent-0107" align="left" valign="top" rowspan="1" colspan="1">0.33 (0.14)</td></tr><tr><td id="dom12494-ent-0108" align="left" valign="top" rowspan="1" colspan="1">Recorded total daily insulin dose, U/kg</td><td id="dom12494-ent-0109" align="left" valign="top" rowspan="1" colspan="1">0.66 (0.23)</td><td id="dom12494-ent-0110" align="left" valign="top" rowspan="1" colspan="1">0.65 (0.17)</td><td id="dom12494-ent-0111" align="left" valign="top" rowspan="1" colspan="1">0.71 (0.18)</td><td id="dom12494-ent-0112" align="left" valign="top" rowspan="1" colspan="1">0.65 (0.23)</td></tr></tbody></table><table-wrap-foot><fn id="dom12494-note-0002"><p>Data are n (%) or mean (standard deviation) in the full analysis set (patients who received &#x02265;1 dose of study medication and had a 24&#x02010;h <styled-content style="fixed-case">UGE</styled-content> value at baseline and at day&#x02009;1 and/or day&#x02009;7). <styled-content style="fixed-case">BMI</styled-content>, body mass index; <styled-content style="fixed-case">DBP</styled-content>, diastolic blood pressure; <styled-content style="fixed-case">eGFR</styled-content>, estimated glomerular filtration rate; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">MDG</styled-content>, mean daily glucose; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; <styled-content style="fixed-case">UGE</styled-content>, urinary glucose excretion.</p></fn><fn id="dom12494-note-0003"><label>*</label><p>
<styled-content style="fixed-case">C</styled-content>hronic <styled-content style="fixed-case">K</styled-content>idney <styled-content style="fixed-case">D</styled-content>isease <styled-content style="fixed-case">E</styled-content>pidemiology <styled-content style="fixed-case">C</styled-content>ollaboration formula.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dom12494-sec-0014"><title>Pharmacodynamics</title><p id="dom12494-para-0021">Empagliflozin 2.5, 10 and 25&#x02009;mg significantly increased 24&#x02010;h UGE compared with placebo on day&#x02009;7 (Figure <xref rid="dom12494-fig-0001" ref-type="fig">1</xref>A). Increases in UGE were observed on day&#x02009;1 and maintained up to day&#x02009;28 (Figure <xref rid="dom12494-fig-0001" ref-type="fig">1</xref>B). On day 28, adjusted mean [standard error (s.e.)] change from baseline in UGE was 0.21 (8.0)&#x02009;g/24&#x02009;h with placebo compared with 79.1 (8.1)&#x02009;g/24&#x02009;h with empagliflozin 2.5&#x02009;mg [adjusted mean difference vs placebo: 78.8&#x02009;g/24&#x02009;h, 95% confidence interval (CI) 56.2, 101.4&#x02009;g/24&#x02009;h; p&#x0003c;0.001], 114.9 (8.1)&#x02009;g/24&#x02009;h with empagliflozin 10&#x02009;mg (adjusted mean difference vs placebo: 114.7&#x02009;g/24&#x02009;h, 95% CI 91.9, 137.5&#x02009;g/24&#x02009;h; p&#x02009;&#x0003c;&#x02009;0.001), and 109.4 (8.3)&#x02009;g/24&#x02009;h with empagliflozin 25&#x02009;mg (adjusted mean difference vs placebo: 109.2&#x02009;g/24&#x02009;h, 95% CI 86.0, 132.3&#x02009;g/24&#x02009;h; p&#x02009;&#x0003c;&#x02009;0.001).</p><fig fig-type="Figure" xml:lang="en" id="dom12494-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(A) Change from baseline in 24&#x02010;h urinary glucose excretion (<styled-content style="fixed-case">UGE</styled-content>) at day&#x02009;7 [analysis of covariance in full analysis set (<styled-content style="fixed-case">FAS</styled-content>), last observation carried forward (<styled-content style="fixed-case">LOCF</styled-content>) imputation]. Data are adjusted mean [standard error (s.e.)]. (B) <styled-content style="fixed-case">UGE</styled-content> over 28&#x02009;days [descriptive statistics in <styled-content style="fixed-case">FAS</styled-content> (<styled-content style="fixed-case">LOCF</styled-content>)]. Data are mean (s.e.) values. <styled-content style="fixed-case">CI</styled-content>, confidence interval.</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-17-928-g001"><alt-text>DOM-12494-FIG-0001-c</alt-text></graphic></fig></sec><sec id="dom12494-sec-0015"><title>Efficacy</title><p id="dom12494-para-0022">Empagliflozin 2.5, 10 and 25&#x02009;mg significantly decreased HbA1c concentrations compared with placebo on day&#x02009;28 (Figure <xref rid="dom12494-fig-0002" ref-type="fig">2</xref>A). Empagliflozin treatment led to dose&#x02010;dependent reductions from baseline in FPG and MDG, which generally did not reach significance compared with placebo (Figure <xref rid="dom12494-fig-0002" ref-type="fig">2</xref>B&#x02013;E).</p><fig fig-type="Figure" xml:lang="en" id="dom12494-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>(A) Change from baseline in glycated haemoglobin (<styled-content style="fixed-case">HbA1c</styled-content>) on day&#x02009;28 [analysis of covariance (<sc>ancova</sc>) in full analysis set (<styled-content style="fixed-case">FAS</styled-content>), last observation carried forward (<styled-content style="fixed-case">LOCF</styled-content>) imputation]. (B) Change from baseline in fasting plasma glucose (<styled-content style="fixed-case">FPG</styled-content>) on day&#x02009;7 (<sc>ancova</sc>, <styled-content style="fixed-case">FAS</styled-content>, <styled-content style="fixed-case">LOCF</styled-content>). (C) Change from baseline in <styled-content style="fixed-case">FPG</styled-content> on day&#x02009;28 (<sc>ancova</sc>, <styled-content style="fixed-case">FAS</styled-content>, <styled-content style="fixed-case">LOCF</styled-content>). (D) Change from baseline in mean daily glucose (<styled-content style="fixed-case">MDG</styled-content>) at day&#x02009;7 (<sc>ancova</sc>, <styled-content style="fixed-case">FAS</styled-content>, <styled-content style="fixed-case">LOCF</styled-content>). (E) Change from baseline in <styled-content style="fixed-case">MDG</styled-content> on day&#x02009;28 (<sc>ancova</sc>, <styled-content style="fixed-case">FAS</styled-content>, <styled-content style="fixed-case">LOCF</styled-content>). (F) Change from baseline in weekly mean total recorded insulin dose within the fourth week of treatment (<sc>ancova</sc>, <styled-content style="fixed-case">FAS</styled-content>, <styled-content style="fixed-case">LOCF</styled-content>). Data are adjusted mean (standard error) values. <styled-content style="fixed-case">CI</styled-content>, confidence interval.</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-17-928-g002"><alt-text>DOM-12494-FIG-0002-c</alt-text></graphic></fig><p id="dom12494-para-0023">Empagliflozin 2.5, 10 and 25&#x02009;mg significantly decreased weekly mean total recorded insulin doses compared with placebo within the fourth week of treatment (Figure <xref rid="dom12494-fig-0002" ref-type="fig">2</xref>F). This reduction was driven by changes in bolus insulin (Figure S1). The weekly mean recorded total, basal and bolus insulin doses over the treatment period are shown in Figure S1. In all groups, carbohydrate intake was increased over the first week of treatment, but decreased during week&#x02009;2 to near baseline levels without substantial changes thereafter (Figure S2).</p><p id="dom12494-para-0024">Empagliflozin 2.5, 10 and 25&#x02009;mg significantly decreased weight compared with placebo. On day&#x02009;28, adjusted mean (s.e.) change from baseline in weight was 0.2 (0.3)&#x02009;kg with placebo compared with &#x02212;1.4 (0.3)&#x02009;kg with empagliflozin 2.5&#x02009;mg [adjusted mean difference vs placebo: &#x02212;1.5 (95% CI &#x02212;2.4, &#x02212;0.7) kg; p&#x02009;&#x0003c;&#x02009;0.001)], &#x02212;1.6 (0.3)&#x02009;kg with empagliflozin 10&#x02009;mg (adjusted mean difference vs placebo: &#x02212;1.8&#x02009;kg, 95% CI &#x02212;2.7, &#x02212;0.9&#x02009;kg; p&#x02009;&#x0003c;&#x02009;0.001), and &#x02212;1.7 (0.3)&#x02009;kg with empagliflozin 25&#x02009;mg (adjusted mean difference vs placebo: &#x02212;1.9&#x02009;kg, 95% CI &#x02212;2.7, &#x02212;1.0&#x02009;kg; p&#x02009;&#x0003c;&#x02009;0.001).</p><p id="dom12494-para-0025">There were no significant differences in changes from baseline in SBP or DBP with empagliflozin compared with placebo. On day&#x02009;28, adjusted mean (s.e.) change from baseline in SBP was 2.8 (2.1)&#x02009;mmHg with placebo compared with 2.7 (2.1)&#x02009;mmHg with empagliflozin 2.5&#x02009;mg, 5.3 (2.1)&#x02009;mmHg with empagliflozin 10&#x02009;mg and 1.2 (2.2)&#x02009;mmHg with empagliflozin 25&#x02009;mg. On day&#x02009;28, adjusted mean (s.e.) change from baseline in DBP was 2.7 (1.3)&#x02009;mmHg with placebo compared with 1.3 (1.3)&#x02009;mmHg with empagliflozin 2.5&#x02009;mg, 3.9 (1.3)&#x02009;mmHg with empagliflozin 10&#x02009;mg, and 2.2 (1.3)&#x02009;mmHg with empagliflozin 25&#x02009;mg.</p></sec><sec id="dom12494-sec-0016"><title>Safety</title><p id="dom12494-para-0026">AEs were reported in 18 (94.7%), 17 (89.5%), 15 (78.9%) and 18 (100.0%) patients on placebo, empagliflozin 2.5&#x02009;mg, empagliflozin 10&#x02009;mg and empagliflozin 25&#x02009;mg, respectively (Table <xref rid="dom12494-tbl-0002" ref-type="table-wrap">2</xref>). AEs regarded as drug&#x02010;related by the investigator were reported in 15 (78.9%), 14 (73.7%), 11 (57.9%) and 18 (100.0%) patients on placebo, empagliflozin 2.5&#x02009;mg, empagliflozin 10&#x02009;mg and empagliflozin 25&#x02009;mg, respectively (Table <xref rid="dom12494-tbl-0002" ref-type="table-wrap">2</xref>); the vast majority of these AEs were hypoglycaemia. There were no discontinuations attributable to AEs. One patient in the placebo group experienced a serious AE (hypoglycaemia). There were no deaths, and no cases of diabetic ketoacidosis were reported. Severe AEs were reported in two patients, both in the placebo group (nasopharyngitis and hypoglycaemia). AEs (MedDRA preferred terms) reported in &#x02265;2 patients in any treatment group were hypoglycaemia, nasopharyngitis, headache, back pain and arthralgia. An AE consistent with UTI was reported in one female patient (on empagliflozin 25&#x02009;mg). This event did not require therapy and did not lead to premature discontinuation of study medication. No AEs consistent with genital infections were reported.</p><table-wrap id="dom12494-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Summary of adverse events and rates of hypoglycaemic episodes per 30&#x02009;days</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="dom12494-ent-0113" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="dom12494-ent-0114" align="left" valign="bottom" rowspan="1" colspan="1">Placebo (n&#x02009;=&#x02009;19)</th><th id="dom12494-ent-0115" align="left" valign="bottom" rowspan="1" colspan="1">Empagliflozin 2.5&#x02009;mg (n&#x02009;=&#x02009;19)</th><th id="dom12494-ent-0116" align="left" valign="bottom" rowspan="1" colspan="1">Empagliflozin 10&#x02009;mg (n&#x02009;=&#x02009;19)</th><th id="dom12494-ent-0117" align="left" valign="bottom" rowspan="1" colspan="1">Empagliflozin 25&#x02009;mg (n&#x02009;=&#x02009;18)</th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" id="dom12494-ent-0118" valign="top" rowspan="1">
<bold>Patients with AEs</bold>
<xref ref-type="fn" rid="dom12494-note-0005">*</xref>
<bold>, n(%)</bold>
</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0119" align="left" valign="top" rowspan="1" colspan="1">One or more AE(s)</td><td id="dom12494-ent-0120" align="left" valign="top" rowspan="1" colspan="1">18 (94.7)</td><td id="dom12494-ent-0121" align="left" valign="top" rowspan="1" colspan="1">17 (89.5)</td><td id="dom12494-ent-0122" align="left" valign="top" rowspan="1" colspan="1">15 (78.9)</td><td id="dom12494-ent-0123" align="left" valign="top" rowspan="1" colspan="1">18 (100.0)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0124" align="left" valign="top" rowspan="1" colspan="1">One or more investigator&#x02010;reported drug&#x02010;related AE(s)</td><td id="dom12494-ent-0125" align="left" valign="top" rowspan="1" colspan="1">15 (78.9)</td><td id="dom12494-ent-0126" align="left" valign="top" rowspan="1" colspan="1">14 (73.7)</td><td id="dom12494-ent-0127" align="left" valign="top" rowspan="1" colspan="1">11 (57.9)</td><td id="dom12494-ent-0128" align="left" valign="top" rowspan="1" colspan="1">18 (100.0)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0129" align="left" valign="top" rowspan="1" colspan="1">One or more AE(s) leading to discontinuation</td><td id="dom12494-ent-0130" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0131" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0132" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0133" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0134" align="left" valign="top" rowspan="1" colspan="1">One or more severe AE(s)</td><td id="dom12494-ent-0135" align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td id="dom12494-ent-0136" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0137" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0138" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0139" align="left" valign="top" rowspan="1" colspan="1">One or more serious AE(s)</td><td id="dom12494-ent-0140" align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td><td id="dom12494-ent-0141" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0142" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0143" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0144" align="left" valign="top" rowspan="1" colspan="1">Deaths</td><td id="dom12494-ent-0145" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0146" align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td id="dom12494-ent-0147" align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td><td id="dom12494-ent-0148" align="left" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" style="padding-left:10%" id="dom12494-ent-0149" valign="top" rowspan="1" colspan="1">AEs reported in &#x02265;2 patients in any group (by preferred term)</td><td align="left" style="padding-left:10%" id="dom12494-ent-0149a" valign="top" rowspan="1" colspan="1"/><td align="left" style="padding-left:10%" id="dom12494-ent-0149b" valign="top" rowspan="1" colspan="1"/><td align="left" style="padding-left:10%" id="dom12494-ent-0149c" valign="top" rowspan="1" colspan="1"/><td align="left" style="padding-left:10%" id="dom12494-ent-0149d" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" id="dom12494-ent-0150" align="left" valign="top" rowspan="1" colspan="1">Hypoglycaemia</td><td id="dom12494-ent-0151" align="left" valign="top" rowspan="1" colspan="1">17 (89.5)</td><td id="dom12494-ent-0152" align="left" valign="top" rowspan="1" colspan="1">16 (84.2)</td><td id="dom12494-ent-0153" align="left" valign="top" rowspan="1" colspan="1">13 (68.4)</td><td id="dom12494-ent-0154" align="left" valign="top" rowspan="1" colspan="1">17 (94.4)</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0155" align="left" valign="top" rowspan="1" colspan="1">Headache</td><td id="dom12494-ent-0156" align="left" valign="top" rowspan="1" colspan="1">3 (15.8)</td><td id="dom12494-ent-0157" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0158" align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td id="dom12494-ent-0159" align="left" valign="top" rowspan="1" colspan="1">6 (33.3)</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0160" align="left" valign="top" rowspan="1" colspan="1">Nasopharyngitis</td><td id="dom12494-ent-0161" align="left" valign="top" rowspan="1" colspan="1">5 (26.3)</td><td id="dom12494-ent-0162" align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td id="dom12494-ent-0163" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0164" align="left" valign="top" rowspan="1" colspan="1">1 (5.6)</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0165" align="left" valign="top" rowspan="1" colspan="1">Back pain</td><td id="dom12494-ent-0166" align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td id="dom12494-ent-0167" align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td><td id="dom12494-ent-0168" align="left" valign="top" rowspan="1" colspan="1">1 (5.3)</td><td id="dom12494-ent-0169" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-165" align="left" valign="top" rowspan="1" colspan="1">Arthralgia</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0170" align="left" valign="top" rowspan="1" colspan="1">Events consistent with UTI<xref ref-type="fn" rid="dom12494-note-0006">&#x02020;</xref>
</td><td id="dom12494-ent-0171" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0172" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0173" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0174" align="left" valign="top" rowspan="1" colspan="1">1 (5.6)</td></tr><tr><td style="padding-left:10%" id="dom12494-ent-0175" align="left" valign="top" rowspan="1" colspan="1">Events consistent with genital infection<xref ref-type="fn" rid="dom12494-note-0007">&#x02021;</xref>
</td><td id="dom12494-ent-0176" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0177" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0178" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td id="dom12494-ent-0179" align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="5" align="left" id="dom12494-ent-0180" valign="top" rowspan="1">
<bold>Rates of hypoglycaemic episodes per 30&#x02009;days</bold>
<xref ref-type="fn" rid="dom12494-note-0008">&#x000a7;</xref>
</td></tr><tr><td colspan="5" align="left" style="padding-left:10%" id="dom12494-ent-0181" valign="top" rowspan="1">
<bold>During week 1 (stable insulin period)</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0182" align="left" valign="top" rowspan="1" colspan="1">Asymptomatic hypoglycaemia with plasma glucose &#x02264;3.9&#x02009;mmol/l</td><td id="dom12494-ent-0183" align="left" valign="top" rowspan="1" colspan="1">7.4</td><td id="dom12494-ent-0184" align="left" valign="top" rowspan="1" colspan="1">9.0</td><td id="dom12494-ent-0185" align="left" valign="top" rowspan="1" colspan="1">10.8</td><td id="dom12494-ent-0186" align="left" valign="top" rowspan="1" colspan="1">10.5</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0187" align="left" valign="top" rowspan="1" colspan="1">Symptomatic hypoglycaemia with plasma glucose &#x02265;3.0 to &#x02264;3.9&#x02009;mmol/l and no need for assistance</td><td id="dom12494-ent-0188" align="left" valign="top" rowspan="1" colspan="1">3.2</td><td id="dom12494-ent-0189" align="left" valign="top" rowspan="1" colspan="1">2.5</td><td id="dom12494-ent-0190" align="left" valign="top" rowspan="1" colspan="1">7.2</td><td id="dom12494-ent-0191" align="left" valign="top" rowspan="1" colspan="1">5.0</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0192" align="left" valign="top" rowspan="1" colspan="1">Symptomatic hypoglycaemia with plasma glucose &#x0003c;3.0&#x02009;mmol/l and no need for assistance</td><td id="dom12494-ent-0193" align="left" valign="top" rowspan="1" colspan="1">0.9</td><td id="dom12494-ent-0194" align="left" valign="top" rowspan="1" colspan="1">0.9</td><td id="dom12494-ent-0195" align="left" valign="top" rowspan="1" colspan="1">1.1</td><td id="dom12494-ent-0196" align="left" valign="top" rowspan="1" colspan="1">1.2</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0197" align="left" valign="top" rowspan="1" colspan="1">Hypoglycaemia requiring assistance</td><td id="dom12494-ent-0198" align="left" valign="top" rowspan="1" colspan="1">0.2</td><td id="dom12494-ent-0199" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0200" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0201" align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td colspan="5" align="left" style="padding-left:10%" id="dom12494-ent-0202" valign="top" rowspan="1">
<bold>During weeks 2&#x02013;4 (flexible insulin period)</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0203" align="left" valign="top" rowspan="1" colspan="1">Asymptomatic hypoglycaemia with plasma glucose &#x02264;3.9&#x02009;mmol/l</td><td id="dom12494-ent-0204" align="left" valign="top" rowspan="1" colspan="1">3.7</td><td id="dom12494-ent-0205" align="left" valign="top" rowspan="1" colspan="1">3.2</td><td id="dom12494-ent-0206" align="left" valign="top" rowspan="1" colspan="1">2.3</td><td id="dom12494-ent-0207" align="left" valign="top" rowspan="1" colspan="1">3.0</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0208" align="left" valign="top" rowspan="1" colspan="1">Symptomatic hypoglycaemia with plasma glucose &#x02265;3.0 to &#x02264;3.9&#x02009;mmol/l and no need for assistance</td><td id="dom12494-ent-0209" align="left" valign="top" rowspan="1" colspan="1">2.9</td><td id="dom12494-ent-0210" align="left" valign="top" rowspan="1" colspan="1">2.4</td><td id="dom12494-ent-0211" align="left" valign="top" rowspan="1" colspan="1">1.7</td><td id="dom12494-ent-0212" align="left" valign="top" rowspan="1" colspan="1">2.9</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0213" align="left" valign="top" rowspan="1" colspan="1">Symptomatic hypoglycaemia with plasma glucose &#x0003c;3.0&#x02009;mmol/l and no need for assistance</td><td id="dom12494-ent-0214" align="left" valign="top" rowspan="1" colspan="1">1.1</td><td id="dom12494-ent-0215" align="left" valign="top" rowspan="1" colspan="1">0.3</td><td id="dom12494-ent-0216" align="left" valign="top" rowspan="1" colspan="1">0.4</td><td id="dom12494-ent-0217" align="left" valign="top" rowspan="1" colspan="1">0.6</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0218" align="left" valign="top" rowspan="1" colspan="1">Hypoglycaemia requiring assistance</td><td id="dom12494-ent-0219" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0220" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0221" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0222" align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td colspan="5" align="left" style="padding-left:10%" id="dom12494-ent-0223" valign="top" rowspan="1">
<bold>Overall (weeks 1&#x02013;4)</bold>
</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0224" align="left" valign="top" rowspan="1" colspan="1">Asymptomatic hypoglycaemia with plasma glucose &#x02264;3.9&#x02009;mmol/l</td><td id="dom12494-ent-0225" align="left" valign="top" rowspan="1" colspan="1">4.6</td><td id="dom12494-ent-0226" align="left" valign="top" rowspan="1" colspan="1">4.6</td><td id="dom12494-ent-0227" align="left" valign="top" rowspan="1" colspan="1">4.4</td><td id="dom12494-ent-0228" align="left" valign="top" rowspan="1" colspan="1">4.8</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0229" align="left" valign="top" rowspan="1" colspan="1">Symptomatic hypoglycaemia with plasma glucose &#x02265;3.0 to &#x02264;3.9&#x02009;mmol/l and no need for assistance</td><td id="dom12494-ent-0230" align="left" valign="top" rowspan="1" colspan="1">2.9</td><td id="dom12494-ent-0231" align="left" valign="top" rowspan="1" colspan="1">2.4</td><td id="dom12494-ent-0232" align="left" valign="top" rowspan="1" colspan="1">3.1</td><td id="dom12494-ent-0233" align="left" valign="top" rowspan="1" colspan="1">3.4</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0234" align="left" valign="top" rowspan="1" colspan="1">Symptomatic hypoglycaemia with plasma glucose &#x0003c;3.0&#x02009;mmol/l and no need for assistance</td><td id="dom12494-ent-0235" align="left" valign="top" rowspan="1" colspan="1">1.0</td><td id="dom12494-ent-0236" align="left" valign="top" rowspan="1" colspan="1">0.4</td><td id="dom12494-ent-0237" align="left" valign="top" rowspan="1" colspan="1">0.5</td><td id="dom12494-ent-0238" align="left" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td style="padding-left:15%" id="dom12494-ent-0239" align="left" valign="top" rowspan="1" colspan="1">Hypoglycaemia requiring assistance</td><td id="dom12494-ent-0240" align="left" valign="top" rowspan="1" colspan="1">0.1</td><td id="dom12494-ent-0241" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0242" align="left" valign="top" rowspan="1" colspan="1">0</td><td id="dom12494-ent-0243" align="left" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="dom12494-note-0004"><p>Data are from the treated set (patients treated with &#x02265;1 dose of study medication). <styled-content style="fixed-case">AE</styled-content>, adverse event; <styled-content style="fixed-case">UTI</styled-content>, urinary tract infection.</p></fn><fn id="dom12494-note-0005"><label>*</label><p>
<styled-content style="fixed-case">AEs</styled-content> reported between the first intake of study medication and up to 7&#x02009;days after the last intake of study medication are shown.</p></fn><fn id="dom12494-note-0006"><label>&#x02020;</label><p>Based on 73 <styled-content style="fixed-case">M</styled-content>edical <styled-content style="fixed-case">D</styled-content>ictionary for <styled-content style="fixed-case">D</styled-content>rug <styled-content style="fixed-case">R</styled-content>egulatory <styled-content style="fixed-case">A</styled-content>ctivities (<styled-content style="fixed-case">MedDRA</styled-content>) preferred terms.</p></fn><fn id="dom12494-note-0007"><label>&#x02021;</label><p>Based on 89 <styled-content style="fixed-case">MedDRA</styled-content> preferred terms.</p></fn><fn id="dom12494-note-0008"><label>&#x000a7;</label><p>Based on episodes reported between the first intake of study medication and up to 1&#x02009;day after the last intake of study medication.</p></fn></table-wrap-foot></table-wrap><p id="dom12494-para-0027">During week&#x02009;1 (stable insulin period), the rates of symptomatic hypoglycaemia with plasma glucose &#x02265;3.0 to &#x02264;3.9&#x02009;mmol/l were higher with empagliflozin 10 and 25&#x02009;mg but lower with empagliflozin 2.5 mg than with placebo, and the rates of symptomatic hypoglycaemia with plasma glucose &#x0003c;3.0&#x02009;mmol/l were similar across treatment groups (Table <xref rid="dom12494-tbl-0002" ref-type="table-wrap">2</xref>). No hypoglycaemic events requiring assistance occurred in empagliflozin groups during week&#x02009;1 (Table <xref rid="dom12494-tbl-0002" ref-type="table-wrap">2</xref>). During weeks&#x02009;2&#x02013;4 (flexible insulin period), the rates of symptomatic hypoglycaemia with plasma glucose &#x02265;3.0 to &#x02264;3.9&#x02009;mmol/l were similar between empagliflozin 2.5, 25&#x02009;mg and placebo and appeared to be lower with empagliflozin 10&#x02009;mg than with placebo, and the rates of symptomatic hypoglycaemia with plasma glucose &#x0003c;3.0&#x02009;mmol/l were generally lower with empagliflozin than with placebo (Table <xref rid="dom12494-tbl-0002" ref-type="table-wrap">2</xref>). No hypoglycaemic events requiring assistance occurred in weeks 2&#x02013;4 (Table <xref rid="dom12494-tbl-0002" ref-type="table-wrap">2</xref>). Over the whole study (including the flexible insulin period), the rates of symptomatic hypoglycaemia with plasma glucose &#x02265;3.0 to &#x02264;3.9&#x02009;mmol/l were 2.9, 2.4, 3.1 and 3.4 episodes per 30&#x02009;days with placebo, empagliflozin 2.5&#x02009;mg, empagliflozin 10&#x02009;mg and empagliflozin 25&#x02009;mg, respectively, and the rates of symptomatic hypoglycaemia with plasma glucose &#x0003c;3.0&#x02009;mmol/l were 1.0, 0.4, 0.5 and 0.8 episodes per 30&#x02009;days with placebo, empagliflozin 2.5&#x02009;mg, empagliflozin 10&#x02009;mg and empagliflozin 25&#x02009;mg, respectively (Table <xref rid="dom12494-tbl-0002" ref-type="table-wrap">2</xref>).</p><p id="dom12494-para-0028">Small increases in haematocrit and &#x003b2;&#x02010;hydroxybutyrate and small decreases in uric acid and eGFR were observed with empagliflozin (Table S1). During routine safety laboratory monitoring, a fasting &#x003b2;&#x02010;hydroxybutyrate level of 5.4&#x02009;mmol/l was observed in a patient on empagliflozin 2.5&#x02009;mg and a level of 2.2&#x02009;mmol/l was observed in a patient on empagliflozin 25&#x02009;mg at week 4. At baseline, these patients had elevated pre&#x02010;treatment &#x003b2;&#x02010;hydroxybutyrate levels of 1.1 and 0.4&#x02009;mmol/l, respectively, and at week 4, total daily insulin doses had been reduced by 51% and 31% in these patients, respectively. The high fasting &#x003b2;&#x02010;hydroxybutyrate levels at week 4 were not considered AEs by the investigator. There were small increases in LDL cholesterol in the empagliflozin 10 and 25&#x02009;mg groups and a small increase in total cholesterol in the empagliflozin 10&#x02009;mg group (Table S1). There were no relevant changes in electrolytes (Table S1).</p></sec></sec><sec id="dom12494-sec-0017"><title>Discussion</title><p id="dom12494-para-0029">This is the first placebo&#x02010;controlled trial to investigate the pharmacodynamics, efficacy and safety of empagliflozin, administered as adjunct to a basal&#x02010;bolus insulin regimen, in patients with type 1 diabetes. This study comprised two treatment phases: a 1&#x02010;week stable insulin period, followed by a 3&#x02010;week flexible insulin period. The stable insulin period allowed direct assessment of the pharmacodynamics and efficacy of the three doses of empagliflozin against a stable insulin regimen. The flexible insulin period was more reflective of clinical practice, in which insulin dose should be adjusted to achieve optimum glycaemic control.</p><p id="dom12494-para-0030">Empagliflozin significantly increased UGE in patients with type 1 diabetes after single drug administration and after 28&#x02009;days of treatment, resulting in significant reductions in HbA1c compared with placebo. Dose&#x02010;dependent reductions in FPG and MDG were observed after 28&#x02009;days, not reaching statistical significance compared with placebo, presumably because of the small sample size. The reductions in HbA1c, FPG and MDG with empagliflozin were achieved together with a significant reduction in daily insulin dose, mostly attributable to reductions in bolus insulin. While rates of moderate hypoglycaemic episodes (symptomatic hypoglycaemia with plasma glucose &#x0003c;3.0&#x02009;mmol/l, not requiring assistance) were similar in the empagliflozin and placebo groups during the stable insulin period, they appeared to be reduced with empagliflozin compared with placebo during the flexible insulin period. Over the entire study, rates of moderate hypoglycaemic episodes were generally lower with empagliflozin than with placebo and no hypoglycaemic episodes requiring assistance were reported with empagliflozin. This is an important clinical finding, as hypoglycaemia is associated with significant morbidity and mortality in patients with type 1 diabetes, while fear of hypoglycaemia is a barrier to adherence to treatment (and so to achieving adequate glycaemic control) and has a negative impact on patients' quality of life <xref rid="dom12494-bib-0020" ref-type="ref">20</xref>, <xref rid="dom12494-bib-0021" ref-type="ref">21</xref>, <xref rid="dom12494-bib-0022" ref-type="ref">22</xref>.</p><p id="dom12494-para-0031">Empagliflozin has consistently been shown to lead to sustained weight loss in patients with type 2 diabetes <xref rid="dom12494-bib-0013" ref-type="ref">13</xref>, <xref rid="dom12494-bib-0014" ref-type="ref">14</xref>, <xref rid="dom12494-bib-0015" ref-type="ref">15</xref>, <xref rid="dom12494-bib-0016" ref-type="ref">16</xref>, <xref rid="dom12494-bib-0017" ref-type="ref">17</xref>, <xref rid="dom12494-bib-0018" ref-type="ref">18</xref>, including those treated with a regimen of multiple daily injections of insulin, likely due to loss of calories in the urine. The majority of weight loss in patients with type 2 diabetes is attributable to a reduction in fat mass, including reductions in both trunk fat and limb fat and in both abdominal visceral and abdominal subcutaneous adipose tissue <xref rid="dom12494-bib-0023" ref-type="ref">23</xref>. Insulin treatment and intensification of insulin treatment often leads to weight gain in patients with type 1 diabetes, which can lead to delays in intensification of therapy and can affect patients' adherence to treatment <xref rid="dom12494-bib-0003" ref-type="ref">3</xref>. Moderate weight loss was observed with empagliflozin as adjunct to insulin in this study, despite the short treatment period.</p><p id="dom12494-para-0032">Empagliflozin was well tolerated in patients with type 1 diabetes. No events consistent with genital infection were reported and there was only one AE consistent with UTI. Similar to findings seen in patients with T2DM, treatment with empagliflozin led to a small increase in haematocrit, which is believed to be attributable to osmotic diuretic effects, and a small increase in LDL cholesterol, possibly attributable to haemoconcentration. Small increases in mean fasting levels of the ketone body &#x003b2;&#x02010;hydroxybutyrate were observed with empagliflozin, probably reflecting glucose and calorie loss and a substrate shift from glucose to lipid utilization associated with the mode of action of empagliflozin <xref rid="dom12494-bib-0024" ref-type="ref">24</xref>. High fasting &#x003b2;&#x02010;hydroxybutyrate levels were observed in two patients on empagliflozin during routine safety laboratory monitoring at week 4, but these were not considered AEs by the investigator. Small changes in eGFR were observed with empagliflozin, likely as a result of haemodynamic changes attributable to effects on tubular&#x02010;feedback mechanisms <xref rid="dom12494-bib-0025" ref-type="ref">25</xref>.</p><p id="dom12494-para-0033">A limitation of the present proof&#x02010;of&#x02010;concept study is its short duration and small sample size. Strengths include that it was a randomized double&#x02010;blind placebo&#x02010;controlled trial and included two treatment phases addressing distinct research questions. The results of this study are consistent with those of the 8&#x02010;week, single&#x02010;arm pilot study of empagliflozin in patients with type 1 diabetes <xref rid="dom12494-bib-0012" ref-type="ref">12</xref> and those of a 2&#x02010;week placebo&#x02010;controlled study of the SGLT2 inhibitor dapagliflozin in patients with type 1 diabetes <xref rid="dom12494-bib-0026" ref-type="ref">26</xref>.</p><p id="dom12494-para-0034">In conclusion, empagliflozin for 28&#x02009;days as adjunct to insulin led to improvements in glycaemic control and reduced body weight accompanied by lower insulin doses compared with placebo in patients with type 1 diabetes. These data suggest that empagliflozin is an adjunct to insulin intervention that could prove to be efficacious in improving the management of type 1 diabetes in larger randomized controlled trials.</p></sec><sec id="dom12494-sec-0019"><title>Conflict of Interest</title><p id="dom12494-para-0037">T. R. P. has served in advisory boards or received speaker honoraria from Novo Nordisk, Eli Lilly, AstraZeneca, Roche Diagnostics and Bristol Meyer Squibb. S. F. has no conflicts of interest to disclose. J. E., J. C., N. S., O. E. J., H. J. W., U. C. B. and S. K. are employees of Boehringer Ingelheim.</p><p id="dom12494-para-0038">T. P. and S. F. contributed to the acquisition and interpretation of data and writing of the manuscript. J. E., J. C., N. S., O. E. J., H. J. W., U. C. B. and S. K. contributed to the study design and interpretation of data and writing of the manuscript. T. R. P. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12494-supitem-0001"><caption><p>
<bold>Figure S1.</bold> (A) Recorded total insulin dose over the treatment period. (B) Recorded basal insulin dose over the treatment period. (C) Recorded bolus insulin dose over the treatment period. Data are mean (standard error).</p></caption><media xlink:href="DOM-17-928-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12494-supitem-0002"><caption><p>
<bold>Figure S2.</bold> Total carbohydrate intake over the treatment period.</p></caption><media xlink:href="DOM-17-928-s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12494-supitem-0003"><caption><p>
<bold>Table S1.</bold> Laboratory results.</p></caption><media xlink:href="DOM-17-928-s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="dom12494-supitem-0004"><caption><p>
<bold>File S1</bold>
<bold>.</bold> List of Investigators.</p></caption><media xlink:href="DOM-17-928-s004.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12494-sec-0018"><title>Acknowledgements</title><p id="dom12494-para-0035">This study was funded by Boehringer Ingelheim and Eli Lilly and Company.</p><p id="dom12494-para-0036">The authors acknowledge the contribution of Tim Heise, Profil Institut f&#x000fc;r Stoffwechselforschung GmbH, Neuss, Germany, to the acquisition and interpretation of data. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of Fleishman&#x02010;Hillard Group, Ltd during the preparation of this article. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development and have approved the final version.</p></ack><ref-list content-type="cited-references" id="dom12494-bibl-0001"><title>References</title><ref id="dom12494-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="dom12494-cit-0001">
<collab collab-type="authors" id="dom12494-gp-0001">American Diabetes Association</collab>
. <article-title>Standards of medical care in diabetes&#x000a0;&#x02013;&#x000a0;2014</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>(Suppl. 1): <fpage>S14</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">24357209</pub-id></mixed-citation></ref><ref id="dom12494-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="dom12494-cit-0002">
<string-name>
<surname>McCrimmon</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Sherwin</surname>
<given-names>RS</given-names>
</string-name>. <article-title>Hypoglycemia in type 1 diabetes</article-title>. <source>Diabetes</source>
<year>2010</year>; <volume>59</volume>: <fpage>2333</fpage>&#x02013;<lpage>2339</lpage>.<pub-id pub-id-type="pmid">20876723</pub-id></mixed-citation></ref><ref id="dom12494-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12494-cit-0003">
<string-name>
<surname>Russell&#x02010;Jones</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>R</given-names>
</string-name>. <article-title>Insulin&#x02010;associated weight gain in diabetes&#x02013;causes, effects and coping strategies</article-title>. <source>Diabetes Obes Metab</source>
<year>2007</year>; <volume>9</volume>: <fpage>799</fpage>&#x02013;<lpage>812</lpage>.<pub-id pub-id-type="pmid">17924864</pub-id></mixed-citation></ref><ref id="dom12494-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12494-cit-0004">
<string-name>
<surname>Nathan</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Cleary</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Backlund</surname>
<given-names>JY</given-names>
</string-name> et&#x02009;al. <article-title>Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes</article-title>. <source>N Engl J Med</source>
<year>2005</year>; <volume>353</volume>: <fpage>2643</fpage>&#x02013;<lpage>2653</lpage>.<pub-id pub-id-type="pmid">16371630</pub-id></mixed-citation></ref><ref id="dom12494-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12494-cit-0005">
<string-name>
<surname>Weinstock</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Xing</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Maahs</surname>
<given-names>DM</given-names>
</string-name> et&#x02009;al. <article-title>Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2013</year>; <volume>98</volume>: <fpage>3411</fpage>&#x02013;<lpage>3419</lpage>.<pub-id pub-id-type="pmid">23760624</pub-id></mixed-citation></ref><ref id="dom12494-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12494-cit-0006">
<string-name>
<surname>Klein</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Knudtson</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Gangnon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>BE</given-names>
</string-name>. <article-title>The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty&#x02010;five&#x02010;year progression of retinopathy in persons with type 1 diabetes</article-title>. <source>Ophthalmology</source>
<year>2008</year>; <volume>115</volume>: <fpage>1859</fpage>&#x02013;<lpage>1868</lpage>.<pub-id pub-id-type="pmid">19068374</pub-id></mixed-citation></ref><ref id="dom12494-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12494-cit-0007">
<string-name>
<surname>de Ferranti</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>de Boer</surname>
<given-names>IH</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>V</given-names>
</string-name> et&#x02009;al. <article-title>Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>2843</fpage>&#x02013;<lpage>2863</lpage>.<pub-id pub-id-type="pmid">25114297</pub-id></mixed-citation></ref><ref id="dom12494-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12494-cit-0008">
<string-name>
<surname>Nordwall</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Abrahamsson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dhir</surname>
<given-names>M</given-names>
</string-name> et&#x02009;al. <article-title>Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden)</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>308</fpage>&#x02013;<lpage>315</lpage>.<pub-id pub-id-type="pmid">25510400</pub-id></mixed-citation></ref><ref id="dom12494-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12494-cit-0009">
<string-name>
<surname>Laing</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Swerdlow</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Slater</surname>
<given-names>SD</given-names>
</string-name> et&#x02009;al. <article-title>Mortality from heart disease in a cohort of 23,000 patients with insulin&#x02010;treated diabetes</article-title>. <source>Diabetologia</source>
<year>2003</year>; <volume>46</volume>: <fpage>760</fpage>&#x02013;<lpage>765</lpage>.<pub-id pub-id-type="pmid">12774166</pub-id></mixed-citation></ref><ref id="dom12494-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12494-cit-0010">
<string-name>
<surname>Grempler</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Eckhardt</surname>
<given-names>M</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin, a novel selective sodium glucose cotransporter&#x02010;2 (SGLT&#x02010;2) inhibitor: characterisation and comparison with other SGLT&#x02010;2 inhibitors</article-title>. <source>Diabetes Obes Metab</source>
<year>2012</year>; <volume>14</volume>: <fpage>83</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">21985634</pub-id></mixed-citation></ref><ref id="dom12494-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12494-cit-0011">
<string-name>
<surname>Heise</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Seewaldt&#x02010;Becker</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Macha</surname>
<given-names>S</given-names>
</string-name> et&#x02009;al. <article-title>Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>
<year>2013</year>; <volume>15</volume>: <fpage>613</fpage>&#x02013;<lpage>621</lpage>.<pub-id pub-id-type="pmid">23356556</pub-id></mixed-citation></ref><ref id="dom12494-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12494-cit-0012">
<string-name>
<surname>Perkins</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Cherney</surname>
<given-names>DZ</given-names>
</string-name>, <string-name>
<surname>Partridge</surname>
<given-names>H</given-names>
</string-name> et&#x02009;al. <article-title>Sodium&#x02010;glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8&#x02010;week open&#x02010;label proof&#x02010;of&#x02010;concept trial</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>1480</fpage>&#x02013;<lpage>1483</lpage>.<pub-id pub-id-type="pmid">24595630</pub-id></mixed-citation></ref><ref id="dom12494-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12494-cit-0013">
<string-name>
<surname>Haering</surname>
<given-names>H&#x02010;U</given-names>
</string-name>, <string-name>
<surname>Merker</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Seewaldt&#x02010;Becker</surname>
<given-names>E</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin as add&#x02010;on to metformin in patients with type 2 diabetes: a 24&#x02010;week, randomized, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>1650</fpage>&#x02013;<lpage>1659</lpage>.<pub-id pub-id-type="pmid">24722494</pub-id></mixed-citation></ref><ref id="dom12494-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12494-cit-0014">
<string-name>
<surname>Haering</surname>
<given-names>H&#x02010;U</given-names>
</string-name>, <string-name>
<surname>Merker</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Seewaldt&#x02010;Becker</surname>
<given-names>E</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin as add&#x02010;on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24&#x02010;week randomized, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Care</source>
<year>2013</year>; <volume>36</volume>: <fpage>3396</fpage>&#x02013;<lpage>3404</lpage>.<pub-id pub-id-type="pmid">23963895</pub-id></mixed-citation></ref><ref id="dom12494-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12494-cit-0015">
<string-name>
<surname>Kovacs</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Seshiah</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Swallow</surname>
<given-names>R</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin improves glycaemic and weight control as add&#x02010;on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24&#x02010;week, randomized, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Obes Metab</source>
<year>2014</year>; <volume>16</volume>: <fpage>147</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">23906415</pub-id></mixed-citation></ref><ref id="dom12494-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12494-cit-0016">
<string-name>
<surname>Roden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Weng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eilbracht</surname>
<given-names>J</given-names>
</string-name> et&#x02009;al. <article-title>Empagliflozin monotherapy in drug&#x02010;na&#x000ef;ve patients with type 2 diabetes: a randomised, 24&#x02010;week, double&#x02010;blind, placebo&#x02010;controlled, parallel group, trial with sitagliptin as active comparator</article-title>. <source>Lancet Diabetes Endocrinol</source>
<year>2013</year>; <volume>1</volume>: <fpage>208</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">24622369</pub-id></mixed-citation></ref><ref id="dom12494-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12494-cit-0017">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jelaska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Frappin</surname>
<given-names>G</given-names>
</string-name> et&#x02009;al. <article-title>Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added&#x02010;on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2014</year>; <volume>37</volume>: <fpage>1815</fpage>&#x02013;<lpage>1823</lpage>.<pub-id pub-id-type="pmid">24929430</pub-id></mixed-citation></ref><ref id="dom12494-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom12494-cit-0018">
<string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jelaska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zeller</surname>
<given-names>C</given-names>
</string-name> et al. <article-title>Impact of empagliflozin added&#x02010;on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78&#x02010;week randomized, double&#x02010;blind, placebo&#x02010;controlled trial</article-title>. <source>Diabetes Obes Metab</source>
<year>2015</year>; <volume>17</volume>: <fpage>936</fpage>&#x02013;<lpage>948</lpage>.<pub-id pub-id-type="pmid">26040302</pub-id></mixed-citation></ref><ref id="dom12494-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12494-cit-0019">
<string-name>
<surname>Vallon</surname>
<given-names>V</given-names>
</string-name>. <article-title>The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus</article-title>. <source>Annu Rev Med</source>
<year>2015</year>; <volume>66</volume>: <fpage>255</fpage>&#x02013;<lpage>270</lpage>.<pub-id pub-id-type="pmid">25341005</pub-id></mixed-citation></ref><ref id="dom12494-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12494-cit-0020">
<string-name>
<surname>Fidler</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Elmelund</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Gillard</surname>
<given-names>S</given-names>
</string-name>. <article-title>Hypoglycemia: an overview of fear of hypoglycemia, quality&#x02010;of&#x02010;life, and impact on costs</article-title>. <source>J Med Econ</source>
<year>2011</year>; <volume>14</volume>: <fpage>646</fpage>&#x02013;<lpage>655</lpage>.<pub-id pub-id-type="pmid">21854191</pub-id></mixed-citation></ref><ref id="dom12494-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12494-cit-0021">
<string-name>
<surname>Awoniyi</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Rehman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Dagogo&#x02010;Jack</surname>
<given-names>S</given-names>
</string-name>. <article-title>Hypoglycemia in patients with type 1 diabetes: epidemiology, pathogenesis, and prevention</article-title>. <source>Curr Diab Rep</source>
<year>2013</year>; <volume>13</volume>: <fpage>669</fpage>&#x02013;<lpage>678</lpage>.<pub-id pub-id-type="pmid">23912765</pub-id></mixed-citation></ref><ref id="dom12494-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12494-cit-0022">
<string-name>
<surname>Cryer</surname>
<given-names>PE</given-names>
</string-name>. <article-title>Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes</article-title>. <source>Diabetologia</source>
<year>2002</year>; <volume>45</volume>: <fpage>937</fpage>&#x02013;<lpage>948</lpage>.<pub-id pub-id-type="pmid">12136392</pub-id></mixed-citation></ref><ref id="dom12494-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12494-cit-0023">
<string-name>
<surname>Ridderstrale</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Zeller</surname>
<given-names>C</given-names>
</string-name> et&#x02009;al. <article-title>Comparison of empagliflozin and glimepiride as add&#x02010;on to metformin in patients with type 2 diabetes: a 104&#x02010;week randomised, active&#x02010;controlled, double&#x02010;blind, phase 3 trial</article-title>. <source>Lancet Diabetes Endocrinol</source>
<year>2014</year>; <volume>2</volume>: <fpage>691</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="pmid">24948511</pub-id></mixed-citation></ref><ref id="dom12494-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12494-cit-0024">
<string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Muscelli</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Frascerra</surname>
<given-names>S</given-names>
</string-name> et&#x02009;al. <article-title>Metabolic response to sodium&#x02010;glucose cotransporter 2 inhibition in type 2 diabetic patients</article-title>. <source>J Clin Invest</source>
<year>2014</year>; <volume>124</volume>: <fpage>499</fpage>&#x02013;<lpage>508</lpage>.<pub-id pub-id-type="pmid">24463454</pub-id></mixed-citation></ref><ref id="dom12494-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12494-cit-0025">
<string-name>
<surname>Cherney</surname>
<given-names>DZ</given-names>
</string-name>, <string-name>
<surname>Perkins</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Soleymanlou</surname>
<given-names>N</given-names>
</string-name> et&#x02009;al. <article-title>Renal hemodynamic effect of sodium&#x02010;glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus</article-title>. <source>Circulation</source>
<year>2014</year>; <volume>129</volume>: <fpage>587</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="pmid">24334175</pub-id></mixed-citation></ref><ref id="dom12494-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom12494-cit-0026">
<string-name>
<surname>Henry</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Rosenstock</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Edelman</surname>
<given-names>S</given-names>
</string-name> et&#x02009;al. <article-title>Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double&#x02010;blind, placebo&#x02010;controlled pilot study</article-title>. <source>Diabetes Care</source>
<year>2015</year>; <volume>38</volume>: <fpage>412</fpage>&#x02013;<lpage>419</lpage>.<pub-id pub-id-type="pmid">25271207</pub-id></mixed-citation></ref></ref-list></back></article>